Every 10-Q that Nkarta, Inc. (NKTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NKTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NKTX filings page.
Nkarta, Inc. is a clinical-stage biotech focused on allogeneic CAR NK cell therapies for autoimmune diseases, led by NKX019. For the quarter ended June 30, 2026, Nkarta reported a net loss of $40.4 million, compared with $23.0 million a year earlier, driven by higher research and development and general and administrative expenses. Research and development expenses rose to $29.0 million in the quarter and $54.0 million for the first half of 2026, primarily reflecting increased clinical and manufacturing spending on NKX019. General and administrative expenses were $14.1 million in the quarter and $20.0 million year-to-date, including about $8.0 million of impairment charges related to equipment, leasehold improvements and right-of-use assets linked to manufacturing consolidation and planned subleasing.
Nkarta ended June 30, 2026 with $243.2 million in cash, cash equivalents, restricted cash and investments, and total stockholders’ equity of $247.7 million
Nkarta, Inc. reported a Q1 2026 net loss of $27.8 million, slightly improved from $32.0 million a year earlier, as it advances engineered NK cell therapies for autoimmune diseases. Research and development expenses were $25.0 million, reflecting continued investment in lead CAR NK candidate NKX019.
General and administrative expenses fell to $5.9 million from $12.4 million, mainly because prior-year severance from a 2025 workforce reduction did not recur. Nkarta ended March 31, 2026 with cash, cash equivalents, restricted cash and investments totaling $266.7 million, and management believes this will fund operations for at least twelve months.
Nkarta, Inc. reported Q3 2025 results. Net loss was $21.7M or $0.29 per share, driven by operating expenses of $27.3M (R&D $20.2M; G&A $7.1M). Other income of $5.6M included $1.7M received for Employee Retention Credit claims, with $1.5M recognized in other income and $0.2M in interest. Year‑to‑date net loss was $76.7M.
Balance sheet and liquidity. Cash, cash equivalents, restricted cash and investments totaled $316.5M as of September 30, 2025 (cash and equivalents $60.1M, short‑term investments $222.2M, long‑term investments $31.4M). Total assets were $427.2M and stockholders’ equity $337.9M. Operating cash use year‑to‑date was $67.1M, while investing activities provided $99.2M. Management believes available funds will meet obligations for at least twelve months from the filing date. The company recorded a $0.8M impairment to right‑of‑use assets and ended with lease liabilities of $76.6M. A March workforce reduction (~34%) carried total severance of $5.4M; $0.7M remained accrued at quarter‑end. Clinically, deep B‑cell depletion was observed with Flu/Cy lymphodepletion, and the iDSMB authorized enrollment in the second dose‑escalation cohort.
Nkarta, Inc. is a clinical-stage biopharmaceutical company developing off-the-shelf engineered NK cell therapies, with lead program NKX019 targeting CD19 for autoimmune diseases. The company continues multiple Phase 1 and investigator-sponsored trials while reprioritizing its pipeline and modifying lymphodepleting conditioning for ongoing studies.
For the three months ended June 30, 2025 Nkarta reported a net loss of $22.98 million and for the six months a net loss of $54.96 million. Research and development was $20.78 million in the quarter and $44.95 million for six months; total operating expenses were $27.19 million in the quarter. As of June 30, 2025 the company had an accumulated deficit of $599.2 million and reported $334.0 million of cash, cash equivalents, restricted cash and investments, which management believes is sufficient to fund operations for at least 12 months.
Operational actions include a March 26, 2025 reduction in force of 53 positions (~34% of workforce) with related severance of approximately $5.4 million, deprioritization of certain programs, and the appointment of Shawn Rose, M.D., Ph.D., as Chief Medical Officer effective June 23, 2025. The balance sheet shows total assets of $448.3 million and operating lease liabilities of $78.5 million.